Now Available: Malignant Melanoma: Update Bulletin [April 2016]

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expanded indication label for Bristol-Myers Squibb's Opdivo plus Yervoy regimen for metastatic melanoma patients regardless of BRAF status; Philogen's pivotal Phase III trials for Darleukin and Fibromun in patients with stage IIIB/C melanoma and the prospects of Provectus Biopharmaceuticals' PV-10 in Phase III trial are also discussed.

* Will Opdivo plus Yervoy combination therapy use increase significantly following BRAF V600 (wild-type & mutation-positive) label expansion?
* Which patient subsets do KOLs think will benefit most from Opdivo plus Yervoy combination?
* What are KOLs expecting from the two year survival data in CheckMate 069?
* How successful do KOLs think Philogen's Darleukin and Fibromun immunocytokines will be in melanoma?
* What safety concerns do KOLs have with Darleukin/Fibromun and which combinations could hold the key to their success?
* What are the prospects of Provectus' PV-10 and how do KOLs view the inclusion of Imlygic as a comparator in Phase III study?

Full Report Details at
- http://www.fastmr.com/prod/1180409_malignant_melanoma_update.aspx?afid=301

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Malignant Melanoma: Update Bulletin [Jan 2016]
- Targeted Therapies In Asthma: Update Bulletin [April 2016]
- Type 2 Diabetes Mellitus: Update Bulletin [April 2016]
- Psoriasis: Update Bulletin [April 2016]
- NSCLC: Update Bulletin [April 2016]